Dynamic Range of Focus of the Eye: Understanding Biomechanics and Kinematics: Part II
IN PART I OF THIS 3-PART series, we outlined the definition of ocular biomechanics and kinematics and described the mechanical laws under which they operate.1 In this article, we describe the specific elements and motions responsible for achieving Dynamic Range of Focus (DRoF), including the phases of vision from accommodation to disaccommodation (near to far) and disaccommodation to accommodation (far to near). The ciliary muscles (CMs) and Bruch’s membrane-choroid complex (BMCC) represent the dynamic engine of DRoF. Interpreting the types of bidirectional forces produced by the critical moving structures during DRoF is essential to understanding the mechanics of the “Kinematic Chain” of events that occur to facilitate the fine-tuned dynamic focusing power our eyes can perform. The aim of this article is to provide a deeper dive into the anatomy and physics of the mechanisms that equip our eyes with DRoF capability and to further explore the elements of this sophisticated mechanism responsible for the adjusting power of the lens.
Explore More Articles
Ace Vision Group Strengthens Executive Team with Addition of Frank Chen as Chief Operating Officer
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering a laser microporation therapy for the aging eye, today announced the appointment of Frank Chen as Chief Operating Officer (COO). Mr. Chen brings extensive management to enhance operational efficiencies and drive business growth at Ace Vision Group (AVG).
read moreThe Answer for Aging Eyes?
The accommodation mechanism is the core moving “engine” of the eye – responsible for dynamic range of visual focus, as well as hydrodynamic equilibrium and circulatory functions. Doesn’t it seem likely that there would be potential ocular health benefits in rejuvenating rigid ocular tissues? Today, there still is no authentic viable therapeutic to rejuvenate ocular …
read moreAce Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read more